The world's top-selling drug Humira is about to lose its place due to newly launched biosimilars. Although AbbVie has introduced a new price policy for Humira, market analysts report that the drug’s market share has rapidly fallen due to competition from biosimilars, including Samsung Bioepis’ I
As the global biosimilar market keeps growing, Korean pharmaceutical companies that have been focusing on traditional drugs are turning their attention to biosimilars. Unlike the newly established large biosimilar companies, these companies follow a strategy to target Japan, which is a niche market,
Samsung Bioepis will launch a collaborative program to help promising biotech startups with overseas clinical trials and product commercialization. The company’s move will provide a big boost to domestic bio startups, which have been hesitant about overseas clinical trials due to high costs.Industry
Celltrion and other biotech shares plunged on August 13 after US investment bank Goldman Sachs reported negatively on biosimilars (a biologic medical product that is almost an identical copy of an original product) producer, Celltrion.Celltrion closed at 260,500 won (US$217) on the securities market